Zelos Therapeutics commences patient dosing of ZT-034 for treating osteoporosis

Full story: Medical News

Zelos Therapeutics, Inc. has initiated patient dosing in a single dose study of three proprietary subcutaneous formulations of ZT-034 , teriparatide). ZT-034 is being developed to compete with Eli Lilly and Companya s Forteo in its existing market of approximately $800M in annual sales in 2008 for the treatment of osteoporosis .

Post

Leave a Comment

Email me Osteoporosis news. Learn more

Comments

Type in your comments to post to the forum

Name
(appears on your post)

Comments

Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Other Recent Osteoporosis Discussions

Topic	Updated	Last By	Comments
Treating osteoporosis early is key to success	Feb 1	normadesmond	2
Some are stopping Fosamax and other osteoporosi... (Jan '06)	Jan 25	James	196
Mixed vibes on body shaker (Jun '06)	Jan 19	FraudPolice	450
Summit Biosciences to expand in Lexington	Dec '09	The REAL Nicci Obama	1
Pfizer Inc. Affirms Confidence In Its Hormone T...	Dec '09	Jeremiah	1
Pfizer Inc. Affirms Confidence In Its Hormone T...	Dec '09	Cheryl H	1
Question About Osteobp.com Online Pharmacy	Dec '09	Elza Stewart	1